Is CSL Limited back in the buy zone?

The CSL Limited (ASX: CSL) share price has come off the boil in recent times, falling from a peak of $143 to today’s price of $129. Is it back in the buy zone?

There are three things any would-be CSL investor should consider at today’s prices:

Financial position

Despite carrying a stack of debt, CSL has a strong financial position with plenty of cash flow. While higher interest rates may have an impact, the chance of the company falling into dire financial straits appears very remote. Thus, an investor’s overall downside is largely protected (the chance of losing 70%-100% of your money appears slim).

Growth prospects

CSL spends heavily on research & development and has several promising treatments in the pipeline, including one which may reduce the likelihood of heart attacks. The company appears to have a good chance of growing its profits from here, although growth will likely be lumpy due to the long lead times on its products, and competition in CSL’s core business.


CSL is priced for a very strong future, with a price to earnings (P/E) ratio of 34, or an enterprise value to EBITDA (EV/EBITDA) of ~25x, both of which are lofty, but not that unusual compared to other high-quality healthcare businesses.

My view is that while CSL is a great business, there’s no need to race out and buy it right now. All of the things propelling it forwards will still be there for the foreseeable future, and its research & development pipeline are setting it up for the long term. That means I can wait for a better price.

Here are 5 companies I'd buy before CSL today:

Rich listers now know the power of dividend shares!

In FY 2018 share market investors are staring down the barrel of ballooning global debt and potential geopolitical powder keg. But thankfully one Foolish expert is revealing 5 of his favorite dividend payers for wealth-creating income whatever the global weather...

But you must act now. This updated report is available for a limited time only, and your copy is 100% free. So don't miss out!

Simply click here to receive your free copy of "Our Top 5 ASX Dividend Shares to Earn You Money in 2018" right now.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.